Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative oncology therapies, primarily targeting non-small cell lung cancer (NSCLC) with uncommon EGFR mutations. Its lead product, firmonertinib, is an oral, mutant-selective tyrosine kinase inhibitor designed to address unmet needs in EGFR-mutated NSCLC, including exon 20 insertion and PACC mutations. The company also develops next-generation antibody drug conjugates (ADCs) for solid tumors, leveraging global partnerships and in-licensing strategies.
This description was generated via AI from an annual report. Updated about 1 year ago.